Journal article

The Cost Differential Between Warfarin Versus Aspirin Treatment After a Fontan Procedure

Chris Schilling, Kim Dalziel, Ajay J Iyengar, Yves d'Udekem



BACKGROUND: The use of aspirin versus warfarin for treatment of patients after a Fontan procedure remains contentious. Current preference-based models of treatment across Australia and New Zealand show variation in care that is unlikely to reflect patient differences and/or clinical risk. METHODS: We combine data from the Australian and New Zealand Fontan Registry and a home INR (International Normalised Ratio) monitoring program (HINRMP) from the Royal Children's Hospital (RCH) Melbourne, to estimate the cost difference for Fontan recipients receiving aspirin versus warfarin for 2015. We adopt a societal perspective to costing which includes cost to the health system (e.g. medical consults,..

View full abstract


Awarded by National Heart Foundation of Australia

Awarded by NHMRC

Funding Acknowledgements

Chris Schilling has received a National Health and Medical Research Council (NHMRC) post- graduate scholarship. Dr Kim Dalziel is a recipient of a McKenzie Fellowship from The University of Melbourne. Dr Ajay J Iyengar has received postgraduate awards from the Royal Australasian College of Surgeons (Catherine Marie Enright Kelly and Eric Bishop Scholarships), the NHMRC and The National Heart Foundation of Australia (1038802). Dr Yves d'Udekem is a Career Development Fellow of The National Heart Foundation of Australia (CR 10M 5339). The Australian and New Zealand Fontan Registry is funded by grants from the NHMRC (Project Grants 1012241, 1047923, 1065794: Partnership Grant 1076849), Heart Kids and the ANZ Bank Trustees.